Washington, United States,
08048034981
Cart
Search
 Washington, United States,
08048034981
+917666132978
Chat with us

Chat with us on WhatsApp

Home
products
Quote
Menu
TYPE 2 DIABETES by Semaglutide

Noveltreat 0.25 mg

Contact Us

Phone Number

08048034981

Please keep 0 before dialling the number.

Email Address citydrug123@gmail.com

Mon-Thu: 10 AM - 2 PM • Fri: 3 PM - 7AM

Address Washington D.C., DC, USA,

Washington, United States,, India, 440012

Description

Noveltreat 0.25 mg (Semaglutide) is a Sun Pharma generic weekly injection for weight management and type 2 diabetes, often tagged for its role in reducing appetite and treating obesity. It is commonly marketed as a pre-filled,, affordable, once-weekly injection to be used alongside diet and exercise for long-term weight management.

Specifications

Active Ingredient Semaglutide
Packaging Typically 2 single-dose pre-filled pens per pack
Drug Class GLP-1 Receptor Agonist
Schedule Once-weekly injection
Dosage 0.25 mg / 0.5 mL

Other Products

view all

6814772a5d263414004dd4a4 Card 2

product image
TYPE 2 DIABETES

Noveltreat 0.25 mg

Noveltreat 0.25 mg (Semaglutide) is a Sun Pharma generic weekly injection for weight management and type 2 diabetes, often tagged for its role in reducing appetite and treating obesity. It is commonly marketed as a pre-filled,, affordable, once-weekly injection to be used alongside diet and exercise for long-term weight management.

6814772a5d263414004dd4a4 Card 2

product image
TYPE 2 DIABETES

Noveltreat 2.4 mg Pre-filled Pen

Sematrinity 4 mg/3 mL Injection is a prescription medication developed by Sun Pharmaceutical Industries in India (launched March 2026) containing the active ingredient semaglutide.It is a GLP-1 receptor agonist designed for the management of type 2 diabetes and sometimes used for weight management, administered as a once-weekly subcutaneous injection .

6814772a5d263414004dd4a4 Card 2

product image
TYPE 2 DIABETES

Sematrinity 1 mg injection

Semaglutide injection products, primarily branded as Ozempic and Wegovy, are GLP-1 receptor agonists designed for weekly, subcutaneous, self-administered weight management and type 2 diabetes treatment. These products are typically indicated for chronic weight management alongside lifestyle changes, or glycemic control in adults.